Arcturus Therapeutics Holdings Inc (ARCT)
17.83
-0.17
(-0.94%)
USD |
NASDAQ |
Nov 04, 16:00
17.83
0.00 (0.00%)
After-Hours: 20:00
Arcturus Therapeutics Holdings Research and Development Expense (Annual): 192.13M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 192.13M |
| December 31, 2022 | 147.75M |
| December 31, 2021 | 173.76M |
| December 31, 2020 | 57.85M |
| December 31, 2019 | 33.64M |
| December 31, 2018 | 16.98M |
| December 31, 2017 | 15.92M |
| Date | Value |
|---|---|
| December 31, 2016 | 17.93M |
| December 31, 2015 | 5.476M |
| December 31, 2014 | 25.10M |
| December 31, 2013 | 7.066M |
| December 31, 2012 | 0.818M |
| December 31, 2011 | 1.822M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
33.64M
Minimum
2019
192.13M
Maximum
2023
121.03M
Average
147.75M
Median
2022
Research and Development Expense (Annual) Benchmarks
| Fulcrum Therapeutics Inc | 71.80M |
| Bioventus Inc | 13.45M |
| Semler Scientific Inc | 5.773M |
| Liquidia Corp | 43.24M |
| Pfizer Inc | 10.68B |